• 瀘州醫(yī)學(xué)院附屬醫(yī)院血管外科(四川瀘州 646000);

目的  評(píng)價(jià)鹽酸沙格雷酯治療慢性下肢動(dòng)脈閉塞癥的有效性和安全性。
方法  對(duì)根據(jù)臨床癥狀、下肢三維血管重建(CTA)或血管造影檢查診斷為慢性下肢動(dòng)脈硬化閉塞癥的32例患者,采用鹽酸沙格雷酯(100 mg/片)治療,1片/次,3次/d,餐后口服,連續(xù)4周。用藥24個(gè)月后觀察患者臨床癥狀的改善情況,分析鹽酸沙格雷酯的治療效果。
結(jié)果  用藥24個(gè)月期間,失訪3例,獲訪29例。綜合療效顯效6例,良好15例,改善5例,無(wú)效3例,總有效率為89.7% (26/29)。治療前后患者的凝血系統(tǒng)和臨床生化各指標(biāo)比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。用藥后3例(10.3%)患者出現(xiàn)輕度惡心和胃部不適,2例(6.9%)患者出現(xiàn)輕度皮疹,其余患者均無(wú)不良反應(yīng)出現(xiàn)。安全性評(píng)價(jià)安全沒(méi)問(wèn)題24例,稍有問(wèn)題5例。
結(jié)論  鹽酸沙格雷酯可以改善慢性下肢動(dòng)脈硬化閉塞癥患者的臨床癥狀。

引用本文: 曾宏,孫曉磊,何虎強(qiáng),劉勇. 鹽酸沙格雷酯治療慢性下肢動(dòng)脈硬化閉塞癥的近期臨床療效觀察. 中國(guó)普外基礎(chǔ)與臨床雜志, 2013, 20(6): 661-663. doi: 復(fù)制

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States:results from the National Health and Nutrition Examination Survey, 1999-2000 [J]. Circulation, 2004, 110(6):738-743.
2. Guan H, Li YJ, Xu ZR, et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China [J]. Chin Med Sci J, 2007, 22(2):83-88.
3. Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) [J]. Pharmacol Rev, 1994, 46(2):157-203.
4. Nagatomo T, Rashid M, Abul Muntasir H, et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system[J]. Pharmacol Ther, 2004, 104(1):59-81.
5. Golino P, Piscione F, Willerson JT, et al. Divergent effects ofserotonin on coronary-artery dimensions and blood flow in patientswith coronary atherosclerosis and control patients [J]. N Engl J Med, 1991, 324(10):641-648.
6. -hydroxytryptamine2C):where structure meets function [J]. Pharmacol Ther, 1998, 79(3):231-257.
7. Saxena PR, Villalón CM. Cardiovascular effects of serotonin agonists and antagonists [J]. J Cardiovasc Pharmacol, 1990, 15 Suppl 7:S17-S34.
8. Roth BL, Willins DL, Kristiansen K, et al. 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B,.
9. 王玉珍, 李翔, 許樟榮, 等. 沙格雷酯與阿司匹林治療糖尿病下肢血管病變的隨機(jī)、對(duì)照臨床研究 [J]. 中華內(nèi)分泌代謝雜志, 2009, 25(6):595-597.
10. Hara H, Osakabe M, Kitajima A, et al. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist [J]. Thromb Haemost, 1991, 65(4):415-420.
11. Nakamura K, Kariyazono H, Moriyama Y, et al. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin [J]. Blood Coagul Fibrinolysis, 1999, 10(8):513-519.
12. Sharma SK, Zahradka P, Chapman D, et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate [J]. J Pharmacol Exp Ther, 1999, 290(3):1475-1481.
13. Maruyama K, Kinami J, Sugita Y, et al. MCI-9042:high affinity for serotonergic receptors as assessed by radioligand binding assay [J]. J Pharmacobiodyn, 1991, 14(4):177-181.
14. He M, Qin X, Cui Y, et al. Prevalence of unrecognized lower extremity peripheral arterial disease and the associated factors in Chinese hypertensive adults [J]. Am J Cardiol, 2012, 110(11):1692-1698.
15. Ma H, Kandil A, Haqqani OP, et al. Endovascular treatment of stenoses in a pediatric patient with incomplete aortic duplication, mesenteric ischemia, and renovascular hypertension [J]. J Vasc Surg, 2013, 57(1):214-217.
16. Cherviakov IuV, Staroverov IN, Nersesian EG, et al. Therapeuticangiogenesis in treatment of patients with chronic obliterating diseases of lower limb arteries [J]. Angiol Sosud Khir, 2012, 18(3):19-27.
  1. 1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States:results from the National Health and Nutrition Examination Survey, 1999-2000 [J]. Circulation, 2004, 110(6):738-743.
  2. 2. Guan H, Li YJ, Xu ZR, et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China [J]. Chin Med Sci J, 2007, 22(2):83-88.
  3. 3. Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) [J]. Pharmacol Rev, 1994, 46(2):157-203.
  4. 4. Nagatomo T, Rashid M, Abul Muntasir H, et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system[J]. Pharmacol Ther, 2004, 104(1):59-81.
  5. 5. Golino P, Piscione F, Willerson JT, et al. Divergent effects ofserotonin on coronary-artery dimensions and blood flow in patientswith coronary atherosclerosis and control patients [J]. N Engl J Med, 1991, 324(10):641-648.
  6. 6. -hydroxytryptamine2C):where structure meets function [J]. Pharmacol Ther, 1998, 79(3):231-257.
  7. 7. Saxena PR, Villalón CM. Cardiovascular effects of serotonin agonists and antagonists [J]. J Cardiovasc Pharmacol, 1990, 15 Suppl 7:S17-S34.
  8. 8. Roth BL, Willins DL, Kristiansen K, et al. 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B,.
  9. 9. 王玉珍, 李翔, 許樟榮, 等. 沙格雷酯與阿司匹林治療糖尿病下肢血管病變的隨機(jī)、對(duì)照臨床研究 [J]. 中華內(nèi)分泌代謝雜志, 2009, 25(6):595-597.
  10. 10. Hara H, Osakabe M, Kitajima A, et al. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist [J]. Thromb Haemost, 1991, 65(4):415-420.
  11. 11. Nakamura K, Kariyazono H, Moriyama Y, et al. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin [J]. Blood Coagul Fibrinolysis, 1999, 10(8):513-519.
  12. 12. Sharma SK, Zahradka P, Chapman D, et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate [J]. J Pharmacol Exp Ther, 1999, 290(3):1475-1481.
  13. 13. Maruyama K, Kinami J, Sugita Y, et al. MCI-9042:high affinity for serotonergic receptors as assessed by radioligand binding assay [J]. J Pharmacobiodyn, 1991, 14(4):177-181.
  14. 14. He M, Qin X, Cui Y, et al. Prevalence of unrecognized lower extremity peripheral arterial disease and the associated factors in Chinese hypertensive adults [J]. Am J Cardiol, 2012, 110(11):1692-1698.
  15. 15. Ma H, Kandil A, Haqqani OP, et al. Endovascular treatment of stenoses in a pediatric patient with incomplete aortic duplication, mesenteric ischemia, and renovascular hypertension [J]. J Vasc Surg, 2013, 57(1):214-217.
  16. 16. Cherviakov IuV, Staroverov IN, Nersesian EG, et al. Therapeuticangiogenesis in treatment of patients with chronic obliterating diseases of lower limb arteries [J]. Angiol Sosud Khir, 2012, 18(3):19-27.
  • 上一篇

    非體外循環(huán)冠狀動(dòng)脈旁路移植術(shù)后早期心肌肌鈣蛋白I檢測(cè)的臨床價(jià)值
  • 下一篇

    二尖瓣置換術(shù)中射頻消融治療慢性心房顫動(dòng)的療效分析